News

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on Neuspera’s innovative integrated sacral ...
Key Takeaways The Co-PSMA trial compares 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT for detecting prostate cancer recurrence post-radical prostatectomy. 64Cu-SAR-bisPSMA has received FDA fast track ...
An expert would summarize that bladder cancer management is evolving from traditional radical surgery toward more personalized, less invasive approaches—highlighting promising therapies like Terra-002 ...
Data showed that African American men faced significant delays in treatment initiation. A recent analysis demonstrated that although African American men and non-African American men had comparable ...
BCAN's $1 million Continuity Grant supports bladder cancer research projects impacted by federal funding terminations, ensuring continued progress in the field. Eligible projects include basic, ...
On Saturday, August 2, 2025, Northwestern University is hosting a course titled "Advances in Genitourinary Robotic Reconstruction." In this video, Ziho Lee, MD, the course director and assistant ...
In this landmark episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with one of the world’s foremost experts in sexual medicine, John P. Mulhall, MD, of Memorial Sloan Kettering Cancer ...
A panelist discusses how different abiraterone formulations require specific steroid combinations—prednisone with traditional abiraterone and prednisolone with microformulation—and the importance of ...
Justin Dubin, MD, discussed how patients' growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.
A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.
Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.